Top Stock Reports for Amgen, FedEx & Thermo Fisher

Thursday, March 22, 2018

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amgen (AMGN), FedEx (FDX) and Thermo Fisher (TMO). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Amgen’s shares have gained +9.4% over the past year, outperforming the Zacks Biomedical and Genetics industry, which has declined -3.3% over the same period. Amgen’s newer drugs – Prolia, Xgeva, Kyprolis – are performing well. Amgen is also progressing with its pipeline and expects approval and launch of migraine candidate, Aimovig this year.

Amgen’s restructuring plan is making it leaner and more cost efficient. Lower taxes and share buybacks should provide some bottom-line support in 2018. However, Amgen has some challenges in store, given slowdown in sales of mature drugs like Enbrel, Aranesp and Neulasta, which are facing an array of branded and generic competitors.

Volume growth of new drugs may not be enough to offset the lost sales due to the decline in mature brands. While Neupogen is already facing U.S. biosimilar competition, Neulasta, Epogen and Sensipar could start facing the same this year. Meanwhile, uptake of key new drug, Repatha has been slow due to payer restrictions.

(You can read the full research report on Amgen here >>>).

Shares of Buy-rated FedEx have outperformed the Zacks Air Freight and Cargo industry and rival United Parcel Service in the last year. The company has gained +31.6% while the industry it belongs to and UPS have rallied +13% and +1.9%, respectively, in the same period.

Ushering in further good news, FedEx outperformed in the third quarter of fiscal 2018 driven by increased package volumes and higher base rates. The company's Ground unit performed very impressively in the quarter.

The Zacks analyst thinks strong e-commerce growth is a huge positive for the company. The new tax law is also encouraging. It was primarily responsible for the company's bullish earnings outlook for fiscal 2018.

Efforts to reward its shareholders through dividend payments and share buybacks are also noteworthy. An uptick in such shareholder-friendly activities cannot be ruled out, in the light of the savings induced by the Tax Cuts and Jobs Act. High costs are, however, hurting the bottom line.

(You can read the full research report on FedEx here >>>).

Buy-rated Thermo Fisher’s shares have outperformed the Zacks Medical Instruments industry over the last three months (+11.9% vs. +9.8%). Post a promising fourth-quarter show by Thermo Fisher, the Zacks analyst is encouraged by the company’s solid international performance with strong growth in the Asia-Pacific and the emerging markets.

Also, a series of product launches along with major progress in precision medicine initiatives benefited the company’s performance. Thermo Fisher’s FEI acquisition has already started to boost analytical instruments portfolio. Also in 2017, the company deployed $ 7.8 billion on strategic acquisitions, adding leading biopharma contract development and manufacturing services through Patheon.

On the flip side, in the reported quarter, the company’s business segments were impacted by strategic investments and unfavorable business mix. Also, competitive headwinds and rising operating costs continue to pose a threat.

(You can read the full research report on Thermo Fisher here >>>).

Other noteworthy reports we are featuring today include Ecolab (ECL), Sherwin-Williams (SHW) and Ameriprise Financial (AMP).

Zacks Editor-in-Chief Goes "All In" on This Stock

Full disclosure, Kevin Matras now has more of his own money in one particular stock than in any other. He believes in its short-term profit potential and also in its prospects to more than double by 2019. Today he reveals and explains his surprising move in a new Special Report.

Download it free >>

Mark Vickery

Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Featured Reports

Jack In the Box’s (JACK) Menu Innovation to Revive Sales

Per the Zacks analyst, Jack in the Box’s focus on menu innovation and operational excellence is likely to drive sales amid a difficult operating environment.

Hormel (HRL) to Benefit From Tax Reform, Turkey Trade Ails

The Zacks analyst thinks higher demand for chief brands will boost Hormel’s near-term results.

Permian Basin to Drive Concho Resources (CXO) Growth

The Zacks analyst likes Concho Resources for its strategic acreage position in the Permian Basin where it holds drilling locations with 8 billion barrels of resource potential.

Valspar Buyout to Aid Sherwin-Williams (SHW) Amid Cost Woes

While Sherwin-Williams should gain from synergies of the Valspar acquisition, hefty costs related to the buyout will weigh on its FY18 earnings, per the Zacks analyst.

Xylem (XYL) Braves Energy Woes With Analytics Trade Pickup

The Zacks analyst thinks that Xylem is countering oil & gas market challenges with improving analytics business as well as water infrastructure services.

Demand for Life-Science Assets aid Alexandria’s (ARE) growth

Per the Zacks analyst, strong fundamentals of the life-science industry have driven demand for Alexandria’s properties.

Global-Industrial Unit Aids Ecolab (ECL) Amid Forex Woes

Ecolab has been gaining prominence in MedTech, thanks to Global-Industrial unit growth in Europe.

New Upgrades

Reorganization Activities to Assist Pentair’s (PNR) Growth

Per the Zacks analyst, Pentair will gain from the separation of Water and Electrical businesses. Rising margins of residential and commercial business will aid results.

Restructuring Efforts to Boost Ameriprise’s (AMP) Profits

Per the Zacks analyst, Ameriprise is well poised for bottom-line growth given its restructuring efforts with focus on core business. Also, a well-diversified portfolio will continue to aid revenues.

New Program Wins, Global Expansion Benefits Plexus (PLXS)

According to the Zacks analyst, Plexus benefits from new program wins as well as continuing global expansion.

New Downgrades

Lower Dayrates & Declining Free Cash Flow Hit Rowan (RDC)

Reducing average dayrates of jackup rigs continues to hurt Rowan, according to the Zacks analyst. A plunge in free operating cash flow is also a cause for concern.

Increasing Expenses & Strict Regulation Hurts IDACORP (IDA)

Per the Zacks analyst compliance with strict regulations and relicensing needs could further increase the rising operating expenses of IDACORP and hurt its margins.

Used Vehicles Margin Pressure Hurts Group 1 Automotive (GPI)

Per the Zacks analyst, used car margin pressure, as well as costs associated with huge investments aimed to strengthen the used vehicle, parts and components, are hurting Group 1 Automotive.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report
The Sherwin-Williams Company (SHW): Free Stock Analysis Report
FedEx Corporation (FDX): Free Stock Analysis Report
Ecolab Inc. (ECL): Free Stock Analysis Report
Ameriprise Financial, Inc. (AMP): Free Stock Analysis Report
Amgen Inc. (AMGN): Free Stock Analysis Report
To read this article on click here.
Zacks Investment Research
Zacks Investment Research – All Commentary Articles

Pin It